Name (Synonyms) | Correlation | |
---|---|---|
drug253 | Cellectra 2000 Electroporation Wiki | 0.50 |
drug802 | Other drugs Wiki | 0.50 |
drug1148 | Therapeutic Anticoagulation Wiki | 0.50 |
drug964 | Reverse-transcription polymerase chain reaction (RT-PCR) Wiki | 0.50 |
drug259 | Chest computed tomography (CT) Wiki | 0.50 |
drug1160 | Thrombin generation test assay Wiki | 0.50 |
drug1066 | Standard of Care thromboprophylaxis Wiki | 0.50 |
drug594 | Intermediate dose thromboprophylaxis Wiki | 0.50 |
drug436 | Fibrin generation markers assays Wiki | 0.50 |
drug1159 | Thrombin Generation Assay (TGA) Wiki | 0.50 |
drug245 | Caption AI Wiki | 0.50 |
drug1161 | Thrombomodulin Modified Thrombin Generation Assay (TGA-TM) Wiki | 0.50 |
drug749 | Niclosamide Wiki | 0.35 |
drug450 | GLS-5300 Wiki | 0.35 |
drug752 | Nitazoxanide Wiki | 0.29 |
drug612 | Ivermectin Wiki | 0.20 |
drug262 | Chloroquine Wiki | 0.19 |
drug431 | Favipiravir Wiki | 0.16 |
Name (Synonyms) | Correlation | |
---|---|---|
D001778 | Blood Coagulation Disorders NIH | 1.00 |
D004211 | Disseminated Intravascular Coagulation NIH | 0.58 |
D016638 | Critical Illness NIH | 0.11 |
D014777 | Virus Diseases NIH | 0.07 |
D007239 | Infection NIH | 0.04 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0001928 | Abnormality of coagulation HPO | 1.00 |
HP:0005521 | Disseminated intravascular coagulation HPO | 0.58 |
There are 4 clinical trials
Inflammation and abnormalities in laboratory coagulation tests are inseparably tied. For example, coagulation abnormalities are nearly universal in septic patients. Coagulation disorders have also been reported in many patients with severe courses of Coronavirus disease 2019 (Covid-19). But it is difficult to assess these changes. Global coagulation tests have been shown to incorrectly assess in vivo coagulation in patients admitted to intensive care units. But other tests are available. Thrombin generation assay (TGA) is a laboratory test which allows the assessment of an individual's potential to generate thrombin. But also in conventional TGA the protein C system is hardly activated because of the absence of endothelial cells (containing natural thrombomodulin) in the plasma sample. Therefore the investigators add recombinant human thrombomodulin to a conventional TGA. Thereby the investigators hope to be able to depict in vivo coagulation more closely than global coagulation tests do.
Description: nM;
Measure: ETP (AUC) without rhThrombomodulin (rhTM) Time: 6 monthsDescription: nM;
Measure: ETP (AUC) with rhThrombomodulin (rhTM) Time: 6 monthsDescription: Ratio of endogenous thrombin potential (ETP) with rhTM to ETP without rhTM
Measure: ETP-ratio Time: 6 monthsDescription: Comparison of ETP-ratios from ICU patients and ETP-ratios from citrated plasma samples from healthy donors
Measure: ETP-Normalisation Time: 6 monthsIncreased D-dimers at admission of COVID-19 infected patients entering hospital due to a severe disease is a risk factor for death. Understanding this acquired coagulopathy is a prerequisite before specific interventional studies. The study investigators aim to apply a normalized and automated thrombin generation test (TGT), developed for testing the thrombotic risk (triggered by 5 pM Tissue Factor, with a purified thrombomodulin (TM) challenge) and to study its association with survival.
Description: Death yes/no during hopstilization, 28 days after admittence
Measure: 28-day survival rate Time: 1 monthDescription: Seconds; without (TM-) and with (TM+) purified thrombomodulin
Measure: Absolute thrombin generation test latent period Time: Day 0Description: %; without (TM-) and with (TM+) purified thrombomodulin
Measure: Relative thrombin generation test latent period compared to reference plasma Time: Day 0Description: nmol/s; without (TM-) and with (TM+) purified thrombomodulin
Measure: Absolute thrombin generation test initial velocity Time: Day 0Description: %; without (TM-) and with (TM+) purified thrombomodulin
Measure: Relative thrombin generation test initial velocity compared to reference plasma Time: Day 0Description: %; without (TM-) and with (TM+) purified thrombomodulin
Measure: Relative thrombin generation test peak thrombin compared to reference plasma Time: Day 0Description: nmol/L; without (TM-) and with (TM+) purified thrombomodulin
Measure: Absolute thrombin generation test peak thrombin Time: Day 0Description: Seconds; without (TM-) and with (TM+) purified thrombomodulin
Measure: Absolute thrombin generation test peak thrombin time Time: Day 0Description: %; without (TM-) and with (TM+) purified thrombomodulin
Measure: Relative thrombin generation test peak thrombin time compared to reference plasma Time: Day 0Description: seconds; without (TM-) and with (TM+) purified thrombomodulin
Measure: Absolute thrombin generation test total thrombin generation time Time: Day 0Description: %; without (TM-) and with (TM+) purified thrombomodulin
Measure: Relative thrombin generation test total thrombin generation time compared to reference plasma Time: Day 0Description: Seconds; without (TM-) and with (TM+) purified thrombomodulin
Measure: Absolute thrombin generation test endogenous thrombin potential Time: Day 0Description: %; without (TM-) and with (TM+) purified thrombomodulin
Measure: Relative thrombin generation test endogenous thrombin potential compared to reference plasma Time: Day 0Description: Death yes/no
Measure: 3-month survival rate Time: 3 monthsDescription: Yes/no
Measure: Transfer to intensive care unit during hospitalization Time: 3 monthsDescription: Yes/no (deep vein thrombosis, pulmonary embolism, atherothrombosis flare, arterial thrombosis)
Measure: Thrombotic complication during hospitalization Time: 3 monthsDescription: µg / L, assayed by automated enzyme linked fluorescent assay (Vidas® D-dimers Exclusion ™ II)
Measure: Plasma concentrations of D-dimers Time: Day 0Description: mg / L, measured by automated immunoagglutination (STA®-Liatest® FM)
Measure: Plasma concentrations of soluble fibrin monomers Time: Day 0This prospective, randomized, open-label, single-center interventional study is designed to compare the safety and efficacy of two LMWH dosing protocols in patients admitted to the University of Iowa Hospitals with COVID-19 who meet the modified ISTH Overt DIC criteria score ≥3. Patients will be randomized to standard prophylactic dose LMWH (standard of care arm) or intermediate-dose LMWH (intervention arm).
Description: Risk of all-cause mortality
Measure: Mortality Time: 30 Days post interventionDescription: Risk of ISTH defined major bleeding
Measure: Major Bleeding Time: 30 Days post interventionDescription: Risk of ischemic stroke, myocardial infarction and/or limb ischemia
Measure: Arterial Thrombosis Time: 30 Days post interventionDescription: Risk of symptomatic venous thromboembolism
Measure: Venous Thromboembolism Time: 30 Days post interventionDescription: duration of intensive care measures
Measure: ICU admission, intubation/ventilation Time: 30 Days post interventionDescription: The number of units of packed red blood cells transfused
Measure: Packed Red Blood Cell Transfusions Time: 30 Days post interventionDescription: The number of units of platelets transfused
Measure: Platelet Transfusions Time: 30 Days post interventionDescription: The number of units of Fresh Frozen Plasma Transfused
Measure: Fresh Frozen Plasma Transfusions Time: 30 Days post interventionDescription: The number of units of Cryoprecipitate Transfused
Measure: Cryoprecipitate Transfusions Time: 30 Days post interventionDescription: The number of units of Prothrombin Complex ConcentrateTransfused
Measure: Prothrombin Complex Concentrate Transfusions Time: 30 Days post interventionDescription: Will be performed in stored plasma using Calibrated Automated Thrombogram. The endogenous thrombin potential will be calculated in units of nM.Min.
Measure: The endogenous thrombin potential will be determined within 24 hours of randomization and weekly for 30 days or until hospital discharge Time: 30 days post interventionDescription: These assays will be performed in stored plasma. Quantification of cfDNA will be performed using Qubit dsDNA HS Assay kit. Histones H4, citrullinated-histone and DNA-myeloperoxidase will be measured using commercially available ELISA kit.
Measure: Plasma levels of cell-free DNA will be determined within 24 hours of randomization and weekly for 30 days or until hospital discharge Time: 30 days post interventionDescription: will be measured in stored plasma using a commercially available ELISA kit.
Measure: PAI-1 Time: 30 days post interventionCoagulopathy of COVID-19 afflicts approximately 20% of patients with severe COVID-19 and is associated with need for critical care and death. COVID-19 coagulopathy is characterized by elevated D-dimer, an indicator of fibrin formation and clot lysis, and a mildly prolonged prothrombin time, suggestive of coagulation consumption. To date, it seems that COVID-19 coagulopathy manifests with thromboembolism, thus anticoagulation may be of benefit. We propose to conduct a parallel pragmatic multi-centre open-label randomized controlled trial to determine the effect of therapeutic anticoagulation compared to standard care in hospitalized patients with COVID-19 and an elevated D-dimer (≥2X upper limit of normal {ULN}).
Description: Composite outcome of ICU admission (yes/no), non-invasive positive pressure ventilation (yes/no), invasive mechanical ventilation (yes/no), or all-cause death (yes/no) up to 28 days.
Measure: Composite outcome of ICU admission (yes/no), non-invasive positive pressure ventilation (yes/no), invasive mechanical ventilation (yes/no), or all-cause death (yes/no) up to 28 days. Time: Up to 28 daysDescription: All-cause death
Measure: All-cause death Time: Up to 28 daysDescription: Composite outcome of ICU admission or all-cause death
Measure: Composite outcome of ICU admission or all-cause death Time: Up to 28 daysDescription: Major bleeding as defined by the ISTH Scientific and Standardization Committee (ISTH-SSC) recommendation
Measure: Major bleeding Time: Up to 28 daysDescription: Red Blood Cell transfusion (greater than or equal to 1 unit)
Measure: Number of participants who received red blood cell transfusion Time: Up to 28 daysDescription: Transfusion of platelets, frozen plasma, prothrombin complex concentrate, cryoprecipitate and/or fibrinogen concentrate
Measure: Number of participants with transfusion of platelets, frozen plasma, prothrombin complex concentrate, cryoprecipitate and/or fibrinogen concentrate. Time: Up to 28 daysDescription: Hospital-free days alive up to day 28
Measure: Number of hospital-free days alive up to day 28 Time: Up to 28 daysDescription: ICU-free days alive up to day 28
Measure: Number of ICU-free days alive up to day 28 Time: Up to 28 daysDescription: Ventilator-free days alive up to day 28
Measure: Number of ventilator-free days alive up to day 28 Time: Up to 28 daysDescription: Venous thromboembolism
Measure: Number of participants with venous thromboembolism Time: Up to 28 daysDescription: Arterial thromboembolism
Measure: Number of participants with arterial thromboembolism Time: Up to 28 daysDescription: Heparin induced thrombocytopenia
Measure: Number of participants with heparin induced thrombocytopenia Time: Up to 28 daysDescription: D-dimer
Measure: Changes in D-dimer up to day 3 Time: Up to day 3